alfentanil
Trade name: alfenta
Approved
Dec 29, 1986
Alfentanil is an opioid analgesic with a rapid onset of action. Alfentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, alfentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Alfentanil may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Alfentanil depresses the respiratory centers, depresses the cough reflex, and constricts the pupils. Alfentanil, marketed under the trade name Alfenta, Rapifen in Australia is indicated for the management of postoperative pain and the maintenance of general anesthesia. — NCATS
Clinical trial activity
38 trials · 49 clinical orgs · 3 marketing orgs
Earliest trial started Aug 1, 1997 (NCT00226564)
Timeline
1980s
- Dec 29, 1986
Akorn, Inc. — Earliest FDA Approval
- Dec 29, 1986
Akorn, Inc. — NDA Secondary Org
- Dec 29, 1986
Akorn, Inc. — NDA Organization
- Dec 29, 1986
Rising Pharmaceuticals — Marketing Organization
1990s
- Oct 28, 1999
Hospira — Marketing Organization
Indications
Approved for
Studied for
- Acne Vulgaris · Phase 3
- Anesthesia · Phase 4
- Biliary Tract Diseases · Phase 4
- Blood Pressure · Phase 4
- Bronchoscopy · Phase 3
- Confusion · Phase 4
- Digestive System Diseases · Phase 4
- Electroconvulsive Therapy · Phase 4
- Emergence Delirium · Phase 4
- Esophageal Sphincter, Lower · Phase 4
- Hypoxia · Phase 4
- Intensive Care Units · Phase 3
- Lung Neoplasms · Phase 4
- Morphine · Phase 3
- Neoplasms · Phase 4
- Pain · Phase 4
- Pancreatic Diseases · Phase 4
- Patient Satisfaction · Phase 4
- Pediatrics · Phase 3
- Procedural Pain · Phase 4
- Procedural Sedation · Phase 4
- Spinal Stenosis · Phase 2/Phase 3
- Venous Cutdown · Phase 4
Mechanism of action
- Mu opioid receptorAGONIST
OPRM agonist
Approval history
- approvedDec 29, 1986
Chemistry & pharmacology
SMILES
CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1- Mol. weight
- 416.53 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL634 ↗
- WikipediaAlfentanil ↗
- NCATS1N74HM2BS7 ↗
- ChEMBLCHEMBL1200531 ↗
Also known as
- afentanyl
- alfenta
- alfenta
- alfenta
- alfentanil
- alfentanil
- alfentanil
- alfentanil
- alfentanil
- alfentanil
- alfentanil
- alfentanil
- alfentanil
- alfentanil hcl
- alfentanil hcl
- alfentanil hcl
- alfentanil hydrochloride
- alfentanil hydrochloride
- alfentanil hydrochloride
- alfentanil hydrochloride
- alfentanil hydrochloride
- alfentanilum
- alfentanilum
- alfentanyl
- alfentanyl
- alfentanyl
- lfentanil hydrochloride
- n-(1-(2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide
- n-(1-(2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide
- r-39209
- r-39209
- rapifen
- rapifen
- rapifen
- rapifen conc
- rapifen dilute
- rapifen intensive care
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07211828 | N/A | Oct 10, 2025 | China Medical University, National Yang Ming Chiao Tung University Hospital |
| NCT06563297 | Phase 4 | Aug 13, 2024 | Kaohsiung Medical University |
| NCT06414018 | N/A | May 20, 2024 | Henan Medical University, Huazhong University of Science and Technology |
| NCT05688384 | Phase 4 | Jan 19, 2023 | Government of Sweden, Region Östergötland |
| NCT04658173 | N/A | Dec 22, 2020 | Tianjin University of Traditional Chinese Medicine |
| NCT03359395 | Phase 4 | Jun 4, 2018 | Wake Forest University |
| NCT02838056 | N/A | Feb 21, 2017 | Taipei Medical University |
| NCT02625181 | N/A | Jul 1, 2016 | University of Washington, Vanderbilt University |
| NCT02646592 | N/A | Apr 1, 2016 | APHP - Hôpital Necker, University of Paris |
| NCT02725723 | Phase 2/Phase 3 (Phase 3) | Mar 1, 2016 | Tel Aviv University |
| NCT02358057 | Phase 4 | Feb 1, 2015 | Université catholique de Louvain |
| NCT02267681 | Phase 4 | Oct 1, 2014 | Ufuk University |
| NCT02000206 | N/A | Feb 1, 2014 | Tel Aviv University |
| NCT04196946 | N/A | Sep 2, 2013 | Nigde Omer Halisdemir University |
| NCT01805726 | Phase 3 | Feb 1, 2013 | Saint-Joseph University |
| NCT02486926 | N/A | Nov 1, 2012 | Hallym University |
| NCT02022488 | Phase 4 | Feb 1, 2012 | Yeditepe University |
| NCT01550354 | N/A | Feb 1, 2012 | Yonsei University |
| NCT01436799 | N/A | Mar 1, 2011 | Gachon University |
| NCT01371968 | N/A | Feb 1, 2011 | Malaysian Society of Anaesthesiologists, University of Malaya |
Organizations
Research & Development (49)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tel Aviv University | Academic/Hospital | 3 | 3 | 2 | 2010 |
| Hennepin Healthcare | Academic/Hospital | 2 | 2 | 1 | 2009 |
| Stanford University | Academic/Hospital | 2 | 2 | 1 | 2008 |
| APHP - Hôpital Necker | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Brazilian Society of Thoracic Surgery | Academic/Hospital | 1 | 0 | 1 | 2007 |
| CareFusion | For profit | 1 | 0 | 1 | 2002 |
| Chang Gung University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| China Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Gachon University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| German Federal Ministry of Education and Research | Government | 1 | 0 | 1 | 2002 |
| Ghent University | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Gloucestershire Hospitals NHS Foundation Trust | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Government of Sweden | Government | 1 | 1 | 1 | 2023 |
| Hallym University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Hebrew University | Academic/Hospital | 1 | 1 | 1 | 1997 |
| Henan Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Hospital Pompeia | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Kaohsiung Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
Marketing (4)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Akorn, Inc. | For profit | NDA2 | Dec 29, 1986 |
| Akorn, Inc. | For profit | NDA | Dec 29, 1986 |
| Hospira | For profit | MKTG | Oct 28, 1999 |
| Rising Pharmaceuticals | For profit | MKTG | Dec 29, 1986 |